USPTO serial 99232608
DIOSYNTH
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- RICKS, AUDREY NICOLE
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with DIOSYNTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $549*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Suzanne M. Hengl
Suzanne M. Hengl Baker Botts L.L.P.44th Floor30 Rockefeller PlazaNew York, NY 10112-4498Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations and substances, namely, chemical additives for use in the manufacturing of pharmaceutical products, namely, chemical preparations and substances for manufacturing pharmaceutical products for veterinary applications; chemical additives for manufacturing medicines, namely, pharmaceuticals; Chemicals, namely, chemical additives for use in the manufacturing of cosmetics, skin cleansers and medicines, namely, pharmaceuticals; chemical preservatives for use in the production of a wide variety for chemicals for pharmaceutical preparations; Biochemicals, namely, polypeptides, recombinant proteins, organic peptide substrates and monoclonal antibodies for scientific purposes, namely, genetic pharmacology | ACTIVE | — |
| 005 | Medicines and pharmaceutical products, namely medicines and pharmaceutical products for veterinary use, namely, medicines and pharmaceutical preparations for the treatment and prevention of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, urological, urogenital disorders and, gastrointestinal disorders, musculoskeletal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, pain, obesity, inflammation and inflammatory disease, respiratory and infectious diseases, immunological, bacterial, viral and fungal disorders, mental illness, depression, psychosis, bone and mineral diseases, infertility, menopausal complaints, hormone deficiencies, and sleep disorders; Medical pharmaceutical preparations, namely, preparations for lowering cholesterol, smoking cessation preparations, tissue and skin repair preparations, dermatological preparations, and gynecological preparations, contraceptives, muscle relaxants, muscle relaxant antagonists; biotechnological preparations, namely, pharmaceutical preparations for medical use, namely use in gene therapy; Biochemicals, namely, biochemical reagent preparations for medical use, namely, for use in gene therapy; genetic material for medical use, namely, genetically engineered tissue for transplant purposes for genetic cell therapy | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Services of biotechnical, chemical and pharmacological laboratories, namely, scientific and technological research, namely, production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations; scientific and technological research, namely, production of chemicals and biotechnological products for use in preparing pharmaceutical and veterinary preparations, and scientific research consultation related thereto; scientific research, namely, conducting early evaluations in the field of new pharmaceutical medicines; development of products for others, namely, pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation and research as related to medical products in the field of new product development in the pharmaceutical and health care industries; scientific analysis and research, namely, evaluation of pharmaceutical products; research and development in the field of pharmaceutical medicines; scientific research and development in the field of medicines; product development for others, namely, preparation of pharmaceutical test products; advisory services relating to the field of scientific research, development and analyses of medicines; development of new technologies for others in the biotechnology sector; providing information about scientific research in the field of biochemistry and biotechnology; scientific research for the medical sector in the field of cancerous diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by FUJIFILM Corporation
- Other trademarks owned by FUJIFILM Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named DIOSYNTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 11, 2026 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Jun 2, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 7, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 13, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 28, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 28, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 28, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 13, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 13, 2025 | NWAP | NEW APPLICATION ENTERED | — |